Dae Gon Ha: Hey good morning, thanks for taking our questions. Clarification question and then one from me on the clarification. So, dosing 20 patients into RUBY by year-end 2023. Do you think that is sufficient to kind of move forward whether it is for regulatory filing or the pivotal trial? And then the question on BD, when it comes to milder conditioning, just wanted to get your preliminary thoughts on where you think the direction is for potential differentiation for you guys. And if it pertains to CD-117, then can you perhaps speak to what areas of differentiation you can actually contemplate here, given the Jasper and Magenta updates? Thanks.
Gilmore O’Neill: Yes, thanks very much Dae Gon. So with regard to the 20, we actually be – that is actually going to generate a lot of very important clinical data with regard to the regulatory needs, that will be a matter of discussion and agreement with the FDA and other regulatory agencies. And that is just something that we are planning over the coming year. Now with regard to milder conditioning and differentiation. I think, there are a number of ways of looking at that. I think the key thing about milder conditioning is that it actually significantly broadens the eligible patient population. Current conditioning is an extremely how should I say, severe therapeutic intervention. And many patients are precluded from using it, just going to significant co-morbidities, which unfortunately result from the long-term complications of their disease.
So mild conditioning per se, doesn’t have to be differentiated to actually substantially broaden the patient population that could benefit from these therapies. And I think, that is an important piece when you actually think about CD-117. With regard to other approaches that is something that we are actively exploring and we will be able to share more as we advance on how we think that differentiates beyond the sort of the general and broad benefit to patients eligibility through the development of milder conditioning.
Dae Gon Ha: Great. Thanks for the updates.
Operator: Our next question is from Phil Nadeau with Cowen & Company. Please proceed.
Phil Nadeau: Good morning. Congrats on the progress and thanks for taking our questions. First a couple on EDIT-301. In terms of the mid-year update in the RUBY trial do you have a preliminary sense as to the number of patients in follow-up that will be in that work? And then on EDIT-301 in TDT, can you remind us, the design similar to RUBY and that the first two patients will be sequential dosing before moving to parallel dosing?
Gilmore O’Neill: Thanks Phil. I’m going to ask our Chief Medical Officer Baisong to answer those two questions.
Baisong Mei: Thank you. Thank you, Phil for your question. Regarding your first question in the middle year of data release, we will not share the number patient this time, but what we can share is that we will share the longer term data for the two patient dose last year and the additional data from multiple patient dosed this year. And we have been not only dosed the sequential dosing the sentinel patient, but also started dosing the parallel dosing for the additional patients. And in addition to that, we have enrolled multiple patients and some of them already been – CD34 cell is being edited and others be in the process of recess. So we are very confident and pleased with the progress of the RUBY trial progress. For your second question, can you repeat again?
Phil Nadeau: Yes, sorry. In terms of 301 and thalassemia is the design the same as the RUBY trial and that the first two patients will be dosed sequentially before you can move on to parallel dosing?
Baisong Mei: Yes. So we will have sentinel patients and we will share more details when we have more of the data.
